542 related articles for article (PubMed ID: 27818234)
1. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
2. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.
John BV; Dang Y; Kaplan DE; Jou JH; Taddei TH; Spector SA; Martin P; Bastaich DR; Chao HH; Dahman B
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):778-788.e7. PubMed ID: 38061410
[TBL] [Abstract][Full Text] [Related]
3. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
Toyoda H; Tada T; Uojima H; Nozaki A; Chuma M; Takaguchi K; Hiraoka A; Abe H; Itobayashi E; Matsuura K; Atsukawa M; Watanabe T; Shimada N; Nakamuta M; Kojima M; Tsuji K; Mikami S; Ishikawa T; Yasuda S; Tsutsui A; Arai T; Kumada T; Tanaka Y; Tanaka J; Chayama K
J Gastroenterol Hepatol; 2024 May; 39(5):949-954. PubMed ID: 38291715
[TBL] [Abstract][Full Text] [Related]
4. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
5. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
[TBL] [Abstract][Full Text] [Related]
6. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
[TBL] [Abstract][Full Text] [Related]
7. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
8. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.
Inoue A; Tsukuma H; Oshima A; Yabuuchi T; Nakao M; Matsunaga T; Kojima J; Tanaka S
J Epidemiol; 2000 Jul; 10(4):234-40. PubMed ID: 10959605
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.
Toyoda H; Kumada T; Tokuda A; Horiguchi Y; Nakano H; Honda T; Nakano S; Hayashi K; Katano Y; Nakano I; Hayakawa T; Nishimura D; Kato K; Imada K; Imoto M; Fukuda Y;
J Viral Hepat; 2000 Nov; 7(6):414-9. PubMed ID: 11115052
[TBL] [Abstract][Full Text] [Related]
11. Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.
Toyoda H; Koshiyama Y; Yasuda S; Kumada T; Chayama K; Akita T; Tanaka J
J Viral Hepat; 2024 Mar; 31(3):137-142. PubMed ID: 38146596
[TBL] [Abstract][Full Text] [Related]
12. Shear-wave elastography to predict hepatocellular carcinoma after hepatitis C virus eradication: A systematic review and meta-analysis.
Esposto G; Santini P; Galasso L; Mignini I; Ainora ME; Gasbarrini A; Zocco MA
World J Gastroenterol; 2024 Mar; 30(10):1450-1460. PubMed ID: 38596502
[TBL] [Abstract][Full Text] [Related]
13. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
Miotto N; Mendes LC; Zanaga LP; Lazarini MSK; Goncales ESL; Pedro MN; Goncales FL; Stucchi RSB; Vigani AG
PLoS One; 2018; 13(7):e0199941. PubMed ID: 29990371
[TBL] [Abstract][Full Text] [Related]
14. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?
Shiratori Y; Omata M
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E141-51. PubMed ID: 10921398
[TBL] [Abstract][Full Text] [Related]
15. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
Lok AS; Seeff LB; Morgan TR; di Bisceglie AM; Sterling RK; Curto TM; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Goodman ZD;
Gastroenterology; 2009 Jan; 136(1):138-48. PubMed ID: 18848939
[TBL] [Abstract][Full Text] [Related]
16. Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history.
Miuma S; Miyaaki H; Ichikawa T; Matsuzaki T; Goto T; Kamo Y; Shigeno M; Hino N; Ario K; Yanagi K; Tsutsumi T; Fukushima N; Nakashiki S; Yamasaki K; Hamasaki K; Shibata H; Arima K; Yamamichi S; Yamashima M; Takahashi K; Nakao Y; Fukushima M; Haraguchi M; Sasaki R; Ozawa E; Taura N; Nakao K
J Med Virol; 2024 Mar; 96(3):e29432. PubMed ID: 38509793
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.
Omata M; Shiratori Y
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E134-40. PubMed ID: 10921397
[TBL] [Abstract][Full Text] [Related]
18. Effects of interferon therapy in "non responder" patients with chronic hepatitis C.
Poynard T; Moussali J; Ratziu V; Regimbeau C; Opolon P
J Hepatol; 1999; 31 Suppl 1():178-83. PubMed ID: 10622583
[TBL] [Abstract][Full Text] [Related]
19. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis.
Tanaka K; Sakai H; Hashizume M; Hirohata T
Jpn J Cancer Res; 1998 Dec; 89(12):1241-50. PubMed ID: 10081484
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area.
Kubicka S; Rudolph KL; Hanke M; Tietze MK; Tillmann HL; Trautwein C; Manns M
Liver; 2000 Jul; 20(4):312-8. PubMed ID: 10959810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
